Selah Genomics, the US subsidiary of UK-based EKF Diagnostics, has launched PrecisionPath Colon, a next-generation sequencing-based test designed to help oncologists make treatment decisions for their colon cancer patients.
The test involves extracting DNA from a patient's tumor tissue and molecularly profiling it use Thermo Fisher Scientific Ion Torrent NGS equipment. Results will be included in a report to a patient's oncologist via a web portal to Selah's laboratory information system. PrecisionPath Colon is priced at $975, and the company said it is offering a maximum seven-day turnaround time.
Selah will offer the test out of one of its two CLIA-certified laboratories in Greenville, South Carolina: one at the Greenville Health System Institute for Translational Oncology Research, where the test was developed; and another at Selah's nearby facility. The test is available to clinicians in the US, except the state of New York, through Selah; and outside the US through EKF.
PrecisionPath Colon will be the first of multiple PrecisionPath products from the company. Selah also eventually plans to offer PrecisionPath Lung and PrecisionPath Breast, among tests for other sites of cancer origin.